Angelman syndrome (AS) is characterised by developmental delay, lack of speech, seizures, a characteristic behavioural profile with a happy demeanour, microcephaly, and ataxia. More than two-thirds of cases are due to an approximately 5-Mb interstitial deletion of the imprinted region 15q11.2q13, which is usually de novo. The rest are associated with point mutations in the UBE3A gene, imprinting defects, and paternal uniparental disomy. Small intragenic UBE3A deletions have rarely been described. They are usually maternally inherited, increasing the recurrence risk to 50%, and may be missed by conventional testing (methylation studies and UBE3A gene sequencing). We describe a boy with AS due to an 11.7-kb intragenic deletion. The deletion was identified by array-CGH and was subsequently detected in his affected first cousin and unaffected maternal grandfather, mother, and aunt, confirming the silencing of the paternal allele. The patient had developmental delay, speech impairment, a happy demeanour, microcephaly, and an abnormal EEG, but no seizures by the age of 4 years. Delineation of the underlying genetic mechanism is of utmost importance for reasons of genetic counselling, as well as appropriate management and prognosis. Alternative techniques, such as array-CGH and MLPA, are necessary when conventional testing for AS has failed to identify the underlying genetic mechanism.

1.
Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, et al: The Ensembl gene annotation system. Database (Oxford) 2016:1-19 (2016).
2.
Beleza-Meireles A, Cerqueira R, Sousa SB, Palmeiro A, Ramos L: Novel deletion encompassing exons 5-12 of the UBE3A gene in a girl with Angelman syndrome. Eur J Med Genet 54:348-350 (2011).
3.
Bird LM: Angelman syndrome: review of clinical and molecular aspects. Appl Clin Genet 7:93-104 (2014).
4.
Boyes L, Wallace AJ, Krajewska-Walasek M, Chrzanowska KH, Clayton-Smith J, Ramsden S: Detection of a deletion of exons 8-16 of the UBE3A gene in familial Angelman syndrome using a semi-quantitative dosage PCR based assay. Eur J Med Genet 49:472-480 (2006).
5.
Buiting K: Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 154C:365-376 (2010).
6.
Cali F, Ragalmuto A, Chiavetta V, Calabrese G, Fichera M, et al: Novel deletion of the E3A ubiquitin protein ligase gene detected by multiplex ligation-dependent probe amplification in a patient with Angelman syndrome. Exp Mol Med 42:842-848 (2010).
7.
Clayton-Smith J, Laan L: Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 40:87-95 (2003).
8.
Dagli A, Buiting K, Williams CA: Molecular and clinical aspects of Angelman syndrome. Mol Syndromol 2:100-112 (2012).
9.
Kyllerman M: On the prevalence of Angelman syndrome. Am J Med Genet 59:405 (1995).
10.
Lawson-Yuen A, Wu BL, Lip V, Sahoo T, Kimonis V: Atypical cases of Angelman syndrome. Am J Med Genet A 140:2361-2364 (2006).
11.
Nazlican H, Zeschnigk M, Claussen U, Michel S, Boehringer S, et al: Somatic mosaicism in patients with Angelman syndrome and an imprinting defect. Hum Mol Genet 13:2547-2555 (2004).
12.
Petersen MB, Brøndum-Nielsen K, Hansen LK, Wulff K: Clinical, cytogenetic, and molecular diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. Am J Med Genet 60:261-262 (1995).
13.
Piard J, Depienne C, Keren B, Fédirko E, Trouillard O, et al: Intragenic deletion of UBE3A gene in 2 sisters with Angelman syndrome detected by MLPA. Am J Med Genet A 155A: 3170-3173 (2011).
14.
Sahoo T, Bacino CA, German JR, Shaw CA, Bird LM, et al: Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype-phenotype correlations. Eur J Hum Genet 15:943-949 (2007).
15.
Valente KD, Varela MC, Koiffmann CP, Andrade JQ, Grossmann R, et al: Angelman syndrome caused by deletion: a genotype-phenotype correlation determined by breakpoint. Epilepsy Res 105:234-239 (2013).
16.
Van Buggenhout G, Fryns JP: Angelman syndrome (AS, MIM 105830). Eur J Hum Genet 17:1367-1373 (2009).
17.
Varela MC, Kok F, Otto PA, Koiffmann CP: Phenotypic variability in Angelman syndrome: comparison among different deletion classes and between deletion and UPD subjects. Eur J Hum Genet 12:987-992 (2004).
18.
Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, et al: Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 140:413-418 (2006).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.